SCHEMBL4769036

SCHEMBL4769036

O=c1c2[nH]c(-c3cnn(-c4ccccc4)c3)cc2n(C2CCC2)c(=O)n1C1CCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 4/20 0.41
ADORA2A P29274 3/20 0.41
ADORA1 P30542 2/20 0.41
MTOR P42345 1/20 0.41
KDM5B Q9UGL1 2/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
DGAT2 Q96PD7 1/20 0.35
GRM4 Q14833 3/20 0.34
ADORA3 P0DMS8 1/20 0.34
HSP90AA1 P07900 1/20 0.34
GRM2 Q14416 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
GRM1 Q13255 1/20 0.34
PDE9A O76083 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771398 0.86 ADORA2A (0.38) ADORA2BADORA2AADORA1MTORKDM5B
SCHEMBL4771400 0.86 ADORA2B (0.42) ADORA2BADORA2AADORA1MTORADORA3
SCHEMBL4763932 0.85 ADORA2B (0.41) ADORA2BADORA2AADORA1MTORADORA3
SCHEMBL4769664 0.83 PIK3CA (0.41) ADORA2BADORA2AMTORCREBBPPIK3CA
SCHEMBL4769040 0.78 ADORA2B (0.47) ADORA2BADORA2AADORA1ADORA3ALDH1A1
SCHEMBL4768977 0.76 ADORA2B (0.49) ADORA2BADORA2AADORA1ADORA3PIK3CA
SCHEMBL4763155 0.75 ADORA2B (0.44) ADORA2BADORA2AADORA1ADORA3PDE9A
SCHEMBL4763154 0.75 BTK (0.40) ADORA2BADORA2AADORA1BRD4CREBBP
SCHEMBL4769043 0.74 ADORA2A (0.42) ADORA2BADORA2AADORA1KDM5BGRM4
SCHEMBL4769743 0.74 ADORA2B (0.58) ADORA2BADORA2AADORA1ADORA3PDE9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678181-B1 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2008-12-31 EP disclosed
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.